General
Preferred name
EVOFOSFAMIDE
Synonyms
TH-302 ()
Evofosfamide (TH-302) ()
TH-302 ()
Evofosfamida ()
HAP-302 ()
P&D ID
PD021567
CAS
918633-87-1
Tags
available
prodrug
covalent binder
drug candidate
Drug indication
Squamous cell carcinoma
Prostate cancer
Neoplasm
Melanoma
Soft tissue sarcoma
Pancreatic cancer
Drug Status
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA
TH-302 combines a 2-nitroimidazole oxygen-sensing trigger with a masked DNA crosslinker. Upon activation in oxygen; deficient zones, TH-302 is converted selectively to the drug's active form, dibromo isophosphoramide mustard, a potent alkylator. TH-302 targets levels of severe hypoxia that are found in tumors but are rare in normal tissues - this is how selective targeting of the tumor occurs. After conversion to the active form of the drug, the hypoxic cells are exposed to high concentrations of released cytotoxic agent, which can also diffuse into the adjacent regions of the tumor.
DESCRIPTION
Evofosfamide is a hypoxia-activated prodrug being investigated as an antineoplastic therapeutic (compound 3b in ). This compound is related to . Being developed by Threshold Pharmaceuticals.
(GtoPdb)
DESCRIPTION
Evofosfamide (TH-302) is a hypoxia-activated proagent with IC50 of 10 ¦ÌM and 1000 ¦ÌM in hypoxia (N2) and normoxia (21% O2), respectively.
PRICE
147
DESCRIPTION
Evofosfamide (TH-302) is a hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) conjugated with 2-nitroimidazole, possessing potential antineoplastic activity. Under hypoxic conditions, typical of hypoxic tumors, the 2-nitroimidazole moiety is reduced, releasing the DNA-alkylating Br-IPM moiety, which induces intra- and inter-strand DNA crosslinks that inhibit DNA replication and cell division, potentially causing apoptosis in tumor cells. The inactive form of the prodrug remains stable under normoxic conditions, which may reduce systemic toxicity.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
7
Organisms
0
Compound Sets
12
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Drugs
CovBinderInPDB
Drug Repurposing Hub
DrugBank
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
26
Molecular Weight
446.93
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
10
Ring Count
1
Aromatic Ring Count
1
cLogP
1.92
TPSA
111.32
Fraction CSP3
0.67
Chiral centers
0.0
Largest ring
5.0
QED
0.24
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Apoptosis
Hypoxia-activated prodrug
MOA
DNA alkylating agent
Source data
